
BTSG Stock Forecast & Price Target
BTSG Analyst Ratings
Bulls say
BrightSpring Health Services Inc. has demonstrated a strong performance in its OP Rehab segment, achieving growth in the double digits and generating attractive margins. The Pharmacy Solutions segment saw significant revenue growth in 2025, with specialty revenue reaching approximately $2.6 billion, reflecting a 43% year-over-year increase and an improving EBITDA margin. Furthermore, the Provider Services division has benefited from strategic acquisitions, showcasing stability and growth in home health and other services, while also positioning BrightSpring to capitalize on the expanding specialty drug market and continued cost savings in healthcare.
Bears say
BrightSpring Health Services Inc. faces a negative outlook primarily due to potential client budget constraints, which could significantly impact its revenue and operational stability. Additionally, a heavy debt load may restrict the company’s ability to invest in growth opportunities, further complicating its financial trajectory. Furthermore, reduced prescription writing by healthcare professionals and decreased drug utilization pose substantial risks that could adversely affect the company's cash flows and operating results.
This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.
BTSG Analyst Forecast & Price Prediction
Start investing in BTSG
Order type
Buy in
Order amount
Est. shares
0 shares